Novartis bags Kesimpta FDA approval for relapsing forms of MS
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) for the treatment of relapsing forms of multiple sclerosis (RMS). The approval is for the use of the anti-CD20 monoclonal antibody (mAb) as a subcutaneous injection in clinically isolated syndrome, […]